Cite

HARVARD Citation

    Smith, P. et al. (2022). Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. Journal of Crohn's and colitis. pp. 1436-1446. [Online]. 
  
Back to record